Press Releases – Page 411

September 29, 2021

Sinocare présente ses produits pour la gestion du diabète et des maladies chroniques lors de la deuxième exposition économique et commerciale Chine-Afrique

CHANGSHA, Chine, 29 septembre 2021 /PRNewswire/ — Sinocare, le leader mondial du développement de tests médicaux, a présenté sa dernière gamme de produits lors de la deuxième exposition économique et commerciale Chine-Afrique (CAETE), qui s’est tenue du 26 au 29 septembre au centre international de congrès et d’expositions de Changsha. Sinocare a présenté, sur le stand qui lui était réservé, différents types de produits pour la gestion des maladies chroniques, notamment le glucomètre, le tensiomètre, le détecteur de lipides sanguins et le détecteur d’acide urique, et a également dévoilé son analyseur multifonction portable analyseur HbA1C portable et son détecteur par fluorescence de produits finis de glycation avancée.

CAETE est une plate-forme importante pour la Chine et les pays africains pour mener une coopération économique et commerciale, et des échanges et dialogues intéressants. Sous le thème « Nouveau départ, nouvelles opportunités, nouvelles réalisations », l’événement de cette année est axé sur les domaines des produits alimentaires et agricoles, des industries médicales et de santé, de la coopération en matière d’infrastructures et de chaînes industrielles, ainsi que de la coopération économique et commerciale approfondie. Sinocare a présenté un certain nombre de produits de pointe qui favoriseront davantage la coopération entre les secteurs médical et de la santé de la Chine et de l’Afrique, et permettront la construction d’une communauté médicale commune.

« Chez Sinocare, notre vision consiste à fournir des produits et des services de haute qualité aux personnes souffrant de diabète et d’autres maladies chroniques afin de les aider à améliorer leur qualité de vie. Nous avons hâte de travailler avec des professionnels de santé et des entreprises privées en Afrique pour fournir à davantage de personnes des solutions accessibles et abordables pour la gestion du diabète », a déclaré Louis Hu, directeur régional de Sinocare pour l’Afrique.

Lors de la CAETE, Sinocare a lancé ses produits phares pour quatre maladies chroniques : le Gold AQ PLUS et le Safe AQ Smart pour la glycémie, l’AES-U111 pour la pression artérielle ; iCARE2100 pour l’analyse multi-index ; et PCH50 pour l’analyse de l’HbA1C. Avec des caractéristiques et des avantages notables, les produits de Sinocare ont attiré l’attention d’innombrables participants qui se sont arrêtés sur le stand pour une consultation.

Gold AQ PLUS possède des propriétés électrochimiques supérieures et une résistance à la corrosion extrêmement importante avec une bandelette de test d’électrode en or pur à 99,99%. Le système est capable de détecter avec précision la température de l’échantillon de sang, le HCT et la température ambiante, et de corriger automatiquement les écarts de résultat. Son autre glucomètre phare exposé était le Safe AQ Smart, doté d’un système FAD-GDH pour des résultats exacts et précis, d’un système d’exploitation facile d’utilisation qui ne nécessite aucun codage et d’une éjection automatique des bandelettes de test.

Pour les patients présentant un taux de cholestérol élevé, le détecteur de lipides et de glycémie à double usage peut être utilisé pour la mesure quantitative du CT, du HDL, des TG et du GLU. Le détecteur a un débit rapide de glucose en 5s et de lipides en 100s, et prend en charge l’impression en ligne par USB et la transmission de données par Bluetooth. Par ailleurs, le système de surveillance de la glycémie et de l’acide urique à double fonction Safe AQ-UG peut être utilisé pour les personnes souffrant de diabète et d’hyperuricémie. Safe AQ UG respecte la norme ISO15197 2013 et est équipé d’une éjection automatique des bandelettes et d’un code intelligent pour les tests d’acide urique.

En outre, iCARE2100 est l’instrument multiplateforme innovant de Sinocare possédant plusieurs indicateurs pour réaliser des tests pratiques au chevet du patient. Alimenté par la technologie principale Liquid Phase iPOCT, iCARE 2100 prend en charge une haute précision et une détection instantanée. Sans utiliser d’autres consommables, les praticiens peuvent réduire les coûts des tests sans compromettre la qualité.

Au-delà de la Chine, Sinocare est présent dans 42 pays d’Afrique, dont l’Algérie, l’Égypte, l’Éthiopie, l’Afrique du Sud et plus encore. L’ensemble de ses ventes à travers le continent ont atteint plus de 110 millions de yuans, les produits les plus populaires de Sinocare étant les systèmes de surveillance de la glycémie, les tensiomètres, les analyseurs de profil lipidique et les détecteurs de HbA1c. La croissance rapide de Sinocare en Afrique s’explique par ses systèmes indolores et faciles à utiliser qui conviennent à un grand nombre de personnes, ainsi que sa stabilité de prélèvement d’échantillons et de bandelette de test avec une technologie brevetée.

Sinocare continue de se développer activement en Afrique et prévoit de créer des usines de production en Algérie et en Égypte pour réaliser la production locale de bandelettes de test de glycémie. Cette initiative réduira considérablement les coûts et le temps de transport, et accélérera ses capacités à fournir aux populations africaines des produits pour la surveillance du diabète.

À propos de Sinocare :

Sinocare compte 19 ans d’expérience dans le secteur des lecteurs de glycémie depuis sa fondation en 2002. La société se consacre au développement, à la production et à la vente de la détection rapide des maladies chroniques grâce à l’utilisation de la technologie des biocapteurs. En 2016, après avoir acquis avec succès Nipro diagnostic Inc. (maintenant renommée Trividia Health Inc.) et PTS Diagnostics Inc., Sinocare est devenu le numéro 5 mondial des fabricants de glucomètres et l’une des principales sociétés au monde d’appareils de test au point de service.

Pour plus d’informations, veuillez consulter le site : www.sinocareintl.com

Facebook : Sinocare In’tl

Contact pour les médias : Echo Gao
Intl_mkt@sinocare.com

Photo – https://mma.prnewswire.com/media/1637313/Sinocare_Headquarters.jpg

September 29, 2021

Adagio Therapeutics Announces New Data Highlighting the Potential of ADG20 for Treatment and Prevention of COVID-19

ADG20 Continues to be Well Tolerated in Healthy Volunteers with Prolonged Half-Life and Serum Virus Neutralization Activity Observed out to Six Months in Ongoing Phase 1 Study

Data from Quantitative Systems Pharmacology/Whole-Body Physiologically Based Pharmacokinetic Modeling Support Evaluation of 300 mg Intramuscular Dose of ADG20 Given as a Single Intramuscular Injection in Ongoing Phase 2/3 Studies

Data to be Presented During IDWeek 2021 and 19^th Annual Discovery on Target Conference

WALTHAM, Mass., Sept. 29, 2021 (GLOBE NEWSWIRE) — Adagio Therapeutics, Inc., (Nasdaq: ADGI) a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of antibody-based solutions for infectious diseases with pandemic potential, today announced new data from the company’s COVID-19 antibody program. Updated, six-month data from its ongoing Phase 1 study of ADG20 in healthy participants and data validating the selection of the 300 mg intramuscular (IM) dose given as a single injection that is being evaluated in the company’s ongoing global Phase 2/3 treatment (STAMP) and prevention (EVADE) clinical trials will be presented during four poster sessions at the Infectious Disease Society of America’s IDWeek 2021, being held from Sept. 29 – Oct. 3, 2021. In addition, Adagio’s chief scientific officer, Laura Walker, Ph.D., will present a subset of the ADG20 Phase 1 data as well as background on the identification and optimization of this differentiated antibody clinical candidate in an oral presentation at the 19^th Annual Discovery on Target Conference on Sept. 30, 2021.

“The continued strength of the safety and pharmacokinetic data from our Phase 1 study is encouraging and further underscores the potential impact an antibody like ADG20 – which was designed to be potent, broadly neutralizing and delivered as a single IM injection – could have on people with or at risk of COVID-19,” said Lynn Connolly, M.D., Ph.D., chief medical officer of Adagio. “These Phase 1 data combined with our dose selection strategy, which relied on our innovative modeling approach, have allowed us to initiate and advance our pivotal trials of ADG20 in the treatment and prevention of COVID-19. We anticipate these data will support an Emergency Use Authorization (EUA) application in the first quarter of 2022, which could enable us to bring an important treatment option to patients.”

Phase 1 Trial Update
Adagio is evaluating ADG20 in a Phase 1 randomized, double-blind, placebo-controlled single ascending-dose study to assess safety and tolerability, pharmacokinetics (PK), immunogenicity, and serum virus neutralizing activity of ADG20 ex vivo against SARS-CoV-2. Data from a six-month evaluation timepoint confirmed the extended half-life of ADG20, which approached 100 days based on data from the 300 mg IM dose that was given as a single injection. In addition, 50% serum virus neutralization titers at six months after a 300 mg IM dose of ADG20 were similar to observed peak titers with the mRNA-1273 vaccine and exceeded those achieved with the AZD1222 vaccine series. Importantly, ADG20 was well tolerated with no study drug-related adverse events (AEs), serious AEs, or injection-site or hypersensitivity reactions reported through a minimum of three months follow-up across all cohorts. Participants will continue to be followed through 12 months to assess safety and tolerability, PK, immunogenicity and serum virus neutralizing activity.

Phase 1 Poster Information: (633) Preliminary Results from a Phase 1 Single Ascending-Dose Study Assessing Safety, Serum Viral Neutralizing Antibody Titers (sVNA), and Pharmacokinetic (PK) Profile of ADG20: an Extended Half-Life Monoclonal Antibody Being Developed for the Treatment and Prevention of Coronavirus Disease (COVID-19)

Dose Selection Strategy
To support dose selection for Adagio’s global Phase 2/3 STAMP and EVADE clinical trials, the company modified an existing quantitative systems pharmacology whole-body physiologically-based pharmacokinetic (QSP/PBPK) model to better characterize the PK of extended half-life monoclonal antibodies in serum and key sites of viral replication in the respiratory tract. Adagio’s model adequately a priori predicted the observed ADG20 serum PK in non-human primates (NHPs) and humans. The model was further optimized based on data from Adagio’s Phase 1 clinical trial and then applied for dose selection for STAMP and EVADE.

For the STAMP treatment trial, data compiled to date suggest that the 300 mg IM regimen has a projected ability to rapidly achieve and maintain target concentrations at key tissue sites of viral replication, including the ability to attain near complete (> 90%) and durable (> 28-day) SARS-CoV-2 receptor occupancy across a range of baseline viral loads. Further, for the EVADE prevention trial, data compiled to date suggest the 300 mg IM regimen has a projected ability to rapidly exceed target serum concentrations in the majority of simulated patients and to maintain potentially effective concentrations for up to 12 months.

Dose Selection Poster Information

(1086) A Whole-Body Quantitative System Pharmacology Physiologically-Based Pharmacokinetic (QSP/PBPK) Model that a priori Predicts Intramuscular (IM) Pharmacokinetics of ADG20: an Extended Half-life Monoclonal Antibody Being Developed for the Treatment and Prevention of Coronavirus Disease (COVID-19)
(1089) Use of a Whole-Body Quantitative System Pharmacology Physiologically-Based Pharmacokinetic (QSP/PBPK) Model to Support Dose Selection of ADG20: an Extended Half-Life Monoclonal Antibody Being Developed for the Prevention of Coronavirus Disease (COVID-19)
(1088) A Whole-Body Quantitative System Pharmacology Physiologically-Based Pharmacokinetic (QSP/PBPK) Model to Support Dose Selection of ADG20: an Extended Half-Life Monoclonal Antibody Being Developed for the Treatment of Coronavirus Disease (COVID-19)

The STAMP and EVADE clinical trials are currently ongoing and enrolling patients globally. For more information, please visit clincialtrials.gov.

About ADG20
ADG20, a monoclonal antibody targeting the spike protein of SARS-CoV-2 and related coronaviruses, is being developed for the prevention and treatment of COVID-19, the disease caused by SARS-CoV-2. ADG20 was designed and engineered to possess high potency and broad neutralization against SARS-CoV-2 and additional clade 1 sarbecoviruses, by targeting a highly conserved epitope in the receptor binding domain. ADG20 displays potent neutralizing activity against the original SARS-CoV-2 strain as well as all known variants of concern. ADG20 has the potential to impact viral replication and subsequent disease through multiple mechanisms of action, including direct blocking of viral entry into the host cell (neutralization) and elimination of infected host cells through Fc-mediated innate immune effector activity. ADG20 is administered by a single intramuscular injection, and was engineered to have a long half-life, with a goal of providing both rapid and durable protection. Adagio is advancing ADG20 through multiple clinical trials on a global basis.

About Adagio Therapeutics
Adagio (Nasdaq: ADGI) is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of antibody-based solutions for infectious diseases with pandemic potential. The company’s portfolio of antibodies has been optimized using Adimab’s industry-leading antibody engineering capabilities and is designed to provide patients and clinicians with a powerful combination of potency, breadth, durable protection (via half-life extension), manufacturability and affordability. Adagio’s portfolio of SARS-CoV-2 antibodies includes multiple, non-competing broadly neutralizing antibodies with distinct binding epitopes, led by ADG20. Adagio has secured manufacturing capacity for the production of ADG20 with third-party contract manufacturers to support the completion of clinical trials and initial commercial launch. For more information, please visit www.adagiotx.com.

Forward Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as “anticipates,” “believes,” “expects,” “intends,” “projects,” and “future” or similar expressions are intended to identify forward-looking statements. Forward-looking statements include statements concerning, among other things, the timing, progress and results of our preclinical studies and clinical trials of ADG20, including the timing of our planned EUA application, initiation and completion of studies or trials and related preparatory work, the period during which the results of the trials will become available and our research and development programs; our ability to obtain and maintain regulatory approvals for, our product candidates; our ability to identify patients with the diseases treated by our product candidates and to enroll these patients in our clinical trials; our manufacturing capabilities and strategy; and our ability to successfully commercialize our product candidates. We may not actually achieve the plans, intentions or expectations disclosed in our forward-looking statements and you should not place undue reliance on our forward-looking statements. These forward-looking statements involve risks and uncertainties that could cause our actual results to differ materially from the results described in or implied by the forward-looking statements, including, without limitation, those risks described under the heading “Risk Factors” in Adagio’s prospectus filed with the Securities and Exchange Commission (“SEC”) on August 6, 2021 and in Adagio’s future reports to be filed with the SEC, including Adagio’s Quarterly Report on Form 10-Q for the quarter ended June 30, 2021. Such risks may be amplified by the impacts of the COVID-19 pandemic. Forward-looking statements contained in this press release are made as of this date, and Adagio undertakes no duty to update such information except as required under applicable law.

Contacts:
Media Contact:
Dan Budwick, 1AB
Dan@1abmedia.com

Investor Contact:
Monique Allaire, THRUST Strategic Communications
monique@thrustsc.com

September 28, 2021

Phoenix Software Delivers First Enhancement to JES3 Technology in Six Years with JES3plus® V1R1

Phoenix Software released updates to its product line in September 2021

EL SEGUNDO, Calif., Sept. 28, 2021 (GLOBE NEWSWIRE) — Phoenix Software International, Inc., today announced the general availability of JES3^plus V1R1, a derivative work based on IBM’s z/OS^® JES3. This release integrates SPOOL I/O performance enhancements made available to JES3^plus customers through continuous delivery earlier this year. This is the first release of the JES3 technology to contain enhancements since early 2015 and coincides with z/OS 2.5, the last release of z/OS to include JES3. Organizations looking to remain on this technology who migrate to JES3^plus can now reap the benefits of an enhanced product with a roadmap for future development.

JES3^plusV1R1

JES3^plus V1R1 supports two newer channel programming techniques to improve performance:

ACKD – channel programs with a shortened prefix that can process an entire track instead of one record at a time. This enhancement leverages MIDAW support.
zHPF – channel programs that leverage the z/Architecture fibre-channel-extensions (FCX) facility to transfer the entire channel program to the device for processing rather than having CCWs transferred as they are encountered.

Phoenix Software’s JES3^plus Customer Advisory Council is actively helping to prioritize the product’s enhancement roadmap, so customers should expect to see additional enhancements delivered in 2022 via continuous delivery.

“We knew early on that enhancing JES3^plus to use the latest I/O techniques would be a priority,” said Ed Jaffe, Chief Technology Officer at Phoenix Software International. “Waiting for a mission-critical JES3 global restart can feel like an eternity and you are sweating bullets the entire time. zHPF reduced that wait by more than 80% in our environment and our customers have enjoyed similar benefits. Much of the credit for the smooth rollout of this new, enhanced JES3^plus release goes to our ISV partners and Early Test participants whose eager participation and incredible patience contributed greatly to this successful launch.”

(E)JES V6R1

(E)JES V6R1, the latest release of Phoenix Software’s modern JESplex management tool, includes enhancements for managing MVS subsystems, understanding address space memory utilization, and searching important system concatenations.

Phoenix Software Product Releases: September 2021

Phoenix Software refreshed its product line this month. Product downloads are available to customers via the Phoenix Software International Support portal. Visit https://phoenixsoftware.com/support.htm#downloads. New product releases include:

(E)JES^® V6R1
CONDOR^® z/OS 26.0 z/VSE 32.0
CYGNET^® z/OS 26.0 z/VSE 32.0
Entrypoint^® 16.2
FALCON^® z/OS 26.0 z/VSE 32.0
Falcon64^® 11.1
ImagEntry^® 4.73
JES3^plus V1R1
Key/101^® 9.1
PHX-Adders^®/PHX-Guest^® 7.3
PHX-KeyPlus^® 5.3
PHX-ODE^® 7.3
Viking Data Entry (VDE) ^® 4.73

About Phoenix Software International

Phoenix Software International, Inc., (https://www.phoenixsoftware.com) is a systems software development company providing advanced software applications to enterprises around the globe. The company offers a wide range of solutions to modern business challenges.

Press contact:
(310) 338-0400
news@phoenixsoftware.com

September 28, 2021

Sinocare Showcases Diabetes and Chronic Diseases Management Products at the Second China-Africa Economic and Trade Expo

CHANGSHA, China, Sept. 28, 2021 /PRNewswire/ — Sinocare, the global leading medical test-developer, has showcased its latest lineup of products at The Second China-Africa Economic and Trade Expo (CAETE), which was held between September 26-29 at the Changsha International Convention and Exhibition Center. In its dedicated booth, Sinocare displayed different type of chronic diseases management products, including blood glucose monitor, blood pressure monitor, blood lipid monitor and uric acid monitor, also unveiled its portable multi-function analyzer, portable HbA1C Analyzer and advanced glycation end of products Fluorescence detector.

CAETE is an important platform for China and African countries to conduct economic and trade cooperation and relevant exchanges and dialogues. With the theme of “New Start, New Opportunities, New Accomplishment”, this year’s event focuses on the fields of food and agricultural products, medical and healthcare industries, infrastructure and industrial chain cooperation, and in-depth economic and trade cooperation. Sinocare showcased a number of industry-leading products that will further promote cooperation between China and Africa’s medical and healthcare industries and aid in the construction of a shared healthcare community.

“At Sinocare, it is our vision to provide high-quality products and services for people with diabetes and other chronic diseases to help them improve their life quality. We look forward to working together with healthcare practitioners and private companies in Africa to provide more people with accessible and affordable diabetes management solutions,” said Louis Hu, Africa Regional Manager of Sinocare.

At CAETE, Sinocare debuted its flagship products for four chronic diseases: the Gold AQ PLUS and Safe AQ Smart for Blood Glucose, AES-U111 for Blood Pressure; iCARE2100 for multi-index analysis; and PCH50 for HbA1C analysis. With clear features and benefits, Sinocare’s products caught the attention of countless attendees who stopped by the booth for a consultation.

Gold AQ PLUS boasts superior electrochemical properties and extremely strong corrosion resistance with a 99.99% pure gold electrode test strip. The system is able to detect blood sample temperature, HCT and ambient temperature accurately, and automatically correct the result deviations. Its other flagship blood glucose monitor on display was the Safe AQ Smart, which features a FAD-GDH system for accurate and precise results, a user-friendly operations system that requires no coding, and automatic test strip ejection.

For patients with high cholesterol, the Dual-Purpose Lipid and Blood Glucose Monitor can be used for the quantitative measurement of TC, HDL, TG and GLU. The monitor has a fast rapid throughput of GLU in 5s and Lipid in 100s, and supports USB online printing and Bluetooth data transmission. Meanwhile, the Safe AQ-UG Dual Function Blood Glucose and Uric Acid Monitoring System can be used for those with diabetes and hyperuricemia. Safe AQ UG is ISO15197 2013 approved and comes equipped with automatic strip ejection and a smart code for uric acid tests.

In addition, iCARE2100 is Sinocare’s innovative cross-platform instrument with multiple indicators for convenient point-of-care testing (POCT). Powered by Liquid Phase iPOCT core technology, iCARE 2100 supports high accuracy and instant detection. Without the use of additional consumables, practitioners can reduce test costs without compromising on quality.

Beyond China, Sinocare is present in 42 countries across Africa, including Algeria, Egypt, Ethiopia, South Africa and more. Its total sales across the continent have reached over RMB 110 million, with the most popular products being Sinocare’s blood glucose monitoring systems, blood pressure monitors, lipid profile analyzers, and HbA1c monitors. Sinocare’s rapid growth in Africa is a result of its painless and easy-to-operate systems that are suitable for a wide range of people, as well as its stable sample collection capabilities and test strip with patented technology.

Sinocare is actively expanding its presence in Africa and plans to establish production plants in Algeria and Egypt to realize the localized production of blood glucose test strips. This move will significantly reduce transportation costs and time and accelerate its capabilities to provide people in Africa with diabetes monitoring products.

About Sinocare:

Sinocare has 19 years experiences in BGM（blood glucose monitor) industry since its foundation in 2002. The company is dedicated to the development, production and sales of the rapid detection of chronic diseases in the use of biosensor technology. In 2016, after the successful acquisition of Nipro diagnostic Inc. (now renamed as Trividia Health Inc.) and PTS Diagnostics Inc. Sinocare has become the world’s No.5 largest blood glucose meter manufacturer and one of the leading companies in POCT industry in the world.

For more information, please visit www.sinocareintl.com

Facebook: Sinocare In’tl

Media Contact: Echo Gao
Intl_mkt@sinocare.com

Photo – https://mma.prnewswire.com/media/1637313/Sinocare_Headquarters.jpg

September 28, 2021

Vinamilk in World’s Top 10 Most Valuable Dairy Brands, Joining Industry Aces in Multiple Categories

HO CHI MINH CITY, Vietnam, Sept. 28, 2021 /PRNewswire/ — Vietnam Dairy Products Joint Stock Company (Vinamilk) has become one of the world’s Most Valuable Dairy Brands with a brand value of US$ 2.4 billion according to the 2021 Brand Finance report. The company also ranked among top positions in three other global food and beverage rankings this year.

Brand Finance is the leading UK-based independent brand valuation and strategy consultancy. Each year, it evaluates 5,000 of the biggest global brands across 23 sectors and rates them based on various criteria.

This year, Vinamilk is ASEAN’s sole representative that secured high positions in four Brand Finance rankings, including the world’s most valuable dairy brands, the dairy brands with the most potential, and the strongest and most valuable food brand rankings.

The result highlights Vinamilk’s growth potential and resilience amid challenges during the COVID-19 pandemic including the disruption of the global supply chain, drop in product demands, and altered consumption habits.

The company has also recently been placed 36^th in the Plimsoll’s 2021 Top 50 global dairy producers by sales revenue, becoming the only Southeast Asian company on the prestigious list.

“After 45 years of continuous development, Vinamilk has reached remarkable position in the global rankings in terms of revenue and brand value. These accomplishments are a testament to our achievements and greatly reinforce our commitment to strive even harder, creating the most nutritious products for both domestic and international consumers and bringing Vietnamese dairy brand further in the global market,” said Ms. Mai Kieu Lien, CEO of Vinamilk.

In addition to maintaining stable production and business, Vinamilk actively carries out community campaigns to promote healthy lifestyle and has stepped up in the fight against COVID-19. Vinamilk supported the country and the international community with financial funding, vaccine donations and more than 6 million products valued at an estimated US$ 4.2 million.

Vinamilk sustains growth momentum amid the pandemic

Vinamilk continues to invest in its international standard farms to ensure the quality of raw milk used in producing domestic and export products

Vinamilk currently has 16 factories, 13 dairy farms worldwide and one large-scale dairy complex project in Laos which supplies more than 250 product SKUs. Amid the pandemic, Vinamilk has continued to maintain stable operation with notable growth in export volume. In the first half of 2021, the company’s export value was estimated at US$ 121.5 million, boasting the double-digit growth rate of 13.1% compared to 2020.

In addition to expanding international reach and become one of the world’s Top 30 leading dairy companies regarding sales revenue, Vinamilk constantly embraces international cooperation to raise its production capability both domestically and abroad.

Vinamilk has subsidiaries and joint ventures in the United States, New Zealand, Laos, Cambodia, and most recently in the Philippines through a joint venture with Del Monte – Philippines’s leading manufacturer and distributor of F&B products. In 2021, the company sets revenue target of US$ 2.7 billion, increase 4.1% year on year.

About VINAMILK

Established in 1976, Vinamilk is the leading nutrition company in Vietnam, serving customers in 56 countries. With the mission of becoming an international brand in food and beverages sector and a trusted brand for consumers in nutritional and health products, Vinamilk is committed to providing high quality products with respect, love and responsibility for life and the community.

Photo – https://mma.prnewswire.com/media/1635463/Vinamilk_image_1.jpg
Photo – https://mma.prnewswire.com/media/1635462/Vinamilk_image_2.jpg
Photo – https://mma.prnewswire.com/media/1635464/Vinamilk_image_3.jpg

September 28, 2021

2Africa Extended to the Arabian Gulf, India, and Pakistan

Now the Longest Subsea Cable System in the World

MENLO PARK, Calif., Sept. 28, 2021 /PRNewswire/ — The 2Africa consortium, comprised of China Mobile International, Facebook, MTN GlobalConnect, Orange, stc, Telecom Egypt, Vodafone and WIOCC, announced today the addition of a new segment – the 2Africa PEARLS branch – extending to the Arabian Gulf, India, and Pakistan. This extension will bring the total length of the 2Africa cable system to over 45,000 kilometers, making it the longest subsea cable system ever deployed.

2Africa Extended to the Arabian Gulf, India, and Pakistan

Now connecting three continents, Africa, Europe and Asia terrestrially through Egypt, 2Africa creates unique connectivity by adding vital landing locations in Oman (Barka), UAE (Abu Dhabi and Kalba), Qatar (Doha), Bahrain (Manama), Kuwait (Kuwait), Iraq (Al-Faw), Pakistan (Karachi), India (Mumbai), and a fourth landing in Saudi Arabia (Al Khobar). The new 2Africa branch joins recently announced extensions to the Canary Islands, the Seychelles, Comoros Islands, Angola, and a new landing to south-east Nigeria.

As with other 2Africa cable landings, capacity will be available in PEARLS landings at carrier-neutral facilities or open-access cable landing stations on a fair and equitable basis, encouraging and supporting the development of a healthy internet ecosystem.

To further support a burgeoning global digital economy, the expanded system will serve an even wider range of communities that rely on the internet for services from education to healthcare, and businesses, providing economic and social benefits that come from increased connectivity. As announced in May 2020, 2Africa was planned to directly bring seamless international connectivity to 1.2 billion people. Today, with 2Africa PEARLS, 2Africa will be providing international connectivity to an additional 1.8 billion people–that’s 3 billion people, representing 36% of the global population.

Alcatel Submarine Networks (ASN) will deploy the new system utilizing new technologies such as SDM that allow the deployment of up to 16 fiber pairs, double that of older technologies and bringing greater and more cost-effective capacity.

About China Mobile International Limited

China Mobile International Limited (CMI) is a wholly-owned subsidiary of China Mobile, mainly responsible for the operation of China Mobile’s international business. In order to provide better services to meet the growing demand in the international telecommunications market, China Mobile established a subsidiary, CMI, in December 2010. CMI currently has over 70 terrestrial and submarine cable resources worldwide, with a total international transmission bandwidth of 98T, and more than 180 PoPs. With Hong Kong, China as its launchpad, CMI has significantly accelerated global IDC development, creating a strong network for data centre cloudification.

Leveraging the strong support by China Mobile, CMI is a trusted partner that provides comprehensive international information services and solutions to international enterprises, carriers and mobile users. Headquartered in Hong Kong, China, CMI has expanded its footprint in 37 countries and regions. For more information, please visit www.cmi.chinamobile.com.

About Facebook

Founded in 2004, Facebook’s mission is to give people the power to build community and bring the world closer together. Over 2 billion people use Facebook, Instagram, WhatsApp, or Messenger every month to stay connected with friends and family, to discover what is going on in the world, and to share and express what matters to them. Facebook is defined by its unique culture – one that rewards impact. The company encourages people to be bold and solve the problems they care most about. The phrase “this journey is 1% finished” reminds the company’s teams that they have only begun to fulfill Facebook’s mission. As the company evolves its journey to bring the world closer together, it stays true to the same core values to guide the way it works and the decisions it makes every step of the way: be open, be bold, move fast, focus on impact, and build social value. For more information, please visit https://www.linkedin.com/company/facebook/about/.

About MTN GlobalConnect

GlobalConnect is a Pan-African digital wholesale and infrastructure services company, and an operating company in the MTN Group. GlobalConnect manages MTN’s international and national major wholesale activities, in addition to offering reliable wholesale and infrastructure solutions for fixed connectivity and wholesale mobility solutions that include international mobile services, Voice, SMS, signalling, roaming and interconnect. The MTN Group launched in 1994 is a leading emerging market operator with a clear vision to lead the delivery of a bold new digital world and is inspired by the belief that everyone deserves the benefits of a modern connected life. Embracing the Ambition 2025 strategy, MTN is anchored on building the largest and most valuable platform business, with a clear focus on Africa. The MTN Group is listed on the JSE Securities Exchange in South Africa under the share code “MTN”.

For more information, please visit www.globalconnect.solutions – https://www.mtn.com

About Orange

Orange is one of the world’s leading telecommunications operators with sales of 42.3 billion euros in 2020 and 139,000 employees worldwide at 30 June 2021, including 80,000 employees in France. The Group has a total customer base of 263 million customers worldwide at 30 June 2021, including 218 million mobile customers and 22 million fixed broadband customers. The Group is present in 26 countries. Orange is also a leading provider of global IT and telecommunication services to multinational companies, under the brand Orange Business Services. In December 2019, the Group presented its new “Engage 2025” strategic plan, which, guided by social and environmental accountability, aims to reinvent its operator model. While accelerating in growth areas and placing data and AI at the heart of its innovation model, the Group will be an attractive and responsible employer, adapted to emerging professions.

Orange is listed on Euronext Paris (symbol ORA) and on the New York Stock Exchange (symbol ORAN).

For more information on the internet and on your mobile: www.orange.com, www.orange-business.com or to follow us on Twitter: @orangegrouppr.

About stc

With its headquarter in Riyadh, stc group is the largest in the Middle East and North Africa based on market cap. stc’s revenue for 2020 amounted to 58,953million SAR (15,721 million US dollars) and the net profit amounted to 10,995 million SAR (2,932 million US dollars). stc was established in 1998 and currently has customers around the globe. It is ranking among the world’s top 50 digital companies and the first in the Middle East and North Africa according to Forbes. It focuses on providing services to enterprise and consumer customers through a fiber-optic network that spans 217,000 kilometers. stc group was among the first in MENA region to launch 5G networks and was considered one of the fastest globally in deploying 5G network as stc already deployed around 4,000 5G towers as end of 2020. stc group has 14 subsidiaries in the Kingdom, gulf and around the world, and its own 100% of stc Bahrain, 51.8% stake in stc Kuwait and 25% stake in Binariang GSM Holding in Malaysia which owns 62% of Maxis in Malaysia.

In Saudi Arabia (the group’s main operation site) stc operates the largest modern mobile network in the Middle East as it covers more than 99% of the country’s populated areas in addition to providing 4G mobile broadband to about 90% of the population across the Kingdom of Saudi Arabia. In addition to the above-mentioned, stc is a strong regional player in IoT, managed services, system integration, cloud computing, information security, big data Analytics fintech and artificial intelligence. For more information, please visit https://www.stc.com.sa; or to follow us on Twitter: @stc , @stc_ksa

About Telecom Egypt

Telecom Egypt is the first total telecom operator in Egypt providing all telecom services to its customers including fixed and mobile voice and data services. Telecom Egypt has a long history serving Egyptian customers for over 160 years maintaining a leadership position in the Egyptian telecom market by offering its enterprise and consumer customers the most advanced technology, reliable infrastructure solutions and the widest network of submarine cables. Aside from its mobile operation “WE”, the company owns a 45% stake in Vodafone Egypt. Telecom Egypt’s shares and GDRs (Ticker: ETEL.CA; TEEG.LN) are traded on The Egyptian Exchange and the London Stock Exchange. Please refer to Telecom Egypt’s full financial disclosure on ir.te.eg

For more information, contact:
The investor relations team
Email: investor.relations@te.eg

About Vodafone

Vodafone is a leading telecommunications company in Europe and Africa. Our purpose is to “connect for a better future” enabling an inclusive and sustainable digital society. Our expertise and scale give us a unique opportunity to drive positive change for society. Our networks keep family, friends, businesses and governments connected and – as COVID-19 has clearly demonstrated – we play a vital role in keeping economies running and the functioning of critical sectors like education and healthcare.

Vodafone is the largest mobile and fixed network operator in Europe and a leading global IoT connectivity provider. Our M-Pesa technology platform in Africa enables 50m people to benefit from access to mobile payments and financial services. We operate mobile and fixed networks in 21 countries and partner with mobile networks in 49 more. As of 30 June 2021, we had over 300m mobile customers, more than 28m fixed broadband customers, over 22m TV customers and we connected 130m IoT devices.

We support diversity and inclusion through our maternity and parental leave policies, empowering women through connectivity and improving access to education and digital skills for women, girls, and society at large. We are respectful of all individuals, irrespective of race, ethnicity, disability, age, sexual orientation, gender identity, belief, culture or religion.

Vodafone is also taking significant steps to reduce our impact on our planet by reducing our greenhouse gas emissions by 50% by 2025 and becoming net zero by 2040, purchasing 100% of our electricity from renewable sources in Europe and across our entire operations by 2025 and reusing, reselling or recycling 100% of our redundant network equipment.

For more information, please visit www.vodafone.com, follow us on Twitter at @VodafoneGroup or connect with us on LinkedIn at www.linkedin.com/company/vodafone.

About WIOCC

WIOCC is building Africa’s first, truly hyper-scale network infrastructure. With the ability to efficiently deliver 100Gbps capacity and an extensive investment programme to develop our pan-African solution even further, WIOCC is the natural partner for OTTs, content providers, telecom operators, and ISPs looking to take advantage of Africa’s opportunities. The company utilises more than 55,000km of terrestrial fibre and in excess of 75,000km of submarine cable assets to offer affordable, reliable, managed connectivity to over 550 locations across 30 African countries. WIOCC’s international reach extends to key commercial centres in Europe, Asia, and North America, providing a one-stop shop for fully-scalable international connectivity into, within, and out of Africa. Operating exclusively as a wholesaler, the company’s focus is on putting you, our client, first. Building and maintaining strong, long-term relationships means WIOCC can develop bespoke solutions to meet your current requirements, with the flexibility to match future demands for growth and extra resilience and geographical expansion. You will find that only WIOCC has the depth of experience, local expertise, capacity, flexibility, and scalability to take you where you want to be. For more information, please visit http://wiocc.net/.

About Alcatel Submarine Networks

Alcatel Submarine Networks, part of Nokia, leads the industry in terms of transmission capacity and installed base with more than 650,000 km of optical submarine systems deployed worldwide, enough to circumnavigate the globe 15 times. From traditional Telecom applications to Content and “Over The Top” Service Provider infrastructures, as well as to offshore Oil and Gas applications, ASN provides all elements of a turnkey global undersea transmission systems, tailored to individual customer’s needs. An extensive Services portfolio completes its comprehensive offering for the submarine business, including project management, installation and commissioning, along with marine and maintenance operations performed by ASN’s fully owned fleet of cable ships. For more information, please visit https://web.asn.com/en/.

Photo – https://mma.prnewswire.com/media/1635450/2Africa___Pearls_Map_Updated.jpg

September 28, 2021

Le professeur Eric Hanushek et le docteur Rukmini Banerji ont reçu le prix Yidan 2021, la plus haute distinction mondiale en matière d’éducation

HONG KONG, 28 septembre 2021 /PRNewswire/ — Le professeur Eric A. Hanushek et le Dr Rukmini Banerji ont reçu le prix Yidan 2021, la plus haute distinction mondiale dans le domaine de l’éducation, en reconnaissance de leurs travaux révolutionnaires portant sur une pièce essentielle du puzzle de l’éducation : l’amélioration à grande échelle de la qualité de l’éducation et des résultats pour les apprenants.

À l’issue d’un processus d’évaluation rigoureux, mené par un comité indépendant composé d’experts reconnus en matière d’éducation, le professeur Eric A. Hanushek et le Dr Rukmini Banerji ont été sélectionnés comme lauréats du prix Yidan 2021 pour la recherche en éducation et du prix Yidan pour le développement de l’éducation. Ils rejoindront les neuf lauréats qui ont reçu le prix Yidan depuis sa création en 2016, établi par la Fondation du prix Yidan – une fondation philanthropique mondiale pour l’éducation qui inspire le progrès et le changement dans l’éducation.

Soutien aux 2021 lauréats pour améliorer la qualité de l’enseignement et les résultats d’apprentissage

Le professeur Eric Hanushek, Paul and Jean Hanna Senior Fellow et professeur à la Hoover Institution de l’université de Stanford, reçoit le prix Yidan 2021 pour la recherche en éducation. Ses travaux, qui portent sur les résultats de l’éducation et l’importance de la qualité de l’enseignement, ont transformé la recherche et les politiques au niveau international. Ses travaux ont contribué à l’élaboration de l’Objectif 4 des Nations Unies pour le Développement Durable (assurer une éducation de qualité inclusive et équitable) en recadrant les objectifs en matière de résultats d’apprentissage et ont montré que c’est la quantité d’apprentissage des étudiants – et non le nombre d’années passées à l’école – qui stimule les économies.

Grâce au financement du prix Yidan, le professeur Hanushek prévoit de mettre en place un programme de chercheurs en Afrique, afin de soutenir la capacité d’analyse pour façonner l’éducation.

Dr Rukmini Banerji is awarded the 2021 Yidan Prize for Education Development, and Professor Eric A. Hanushek is awarded the 2021 Yidan Prize for Education Research.

Le Dr Rukmini Banerji, Directeur général de Pratham Education Foundation, reçoit le Prix Yidan 2021 pour le développement de l’éducation pour son travail visant à améliorer les résultats de l’apprentissage. L’approche d’évaluation du Rapport Annuel sur le Résultats de l’Education (ASER), mise au point par le Dr Banerji et son équipe, a révélé des lacunes en matière de lecture et de calcul chez des enfants qui avaient déjà passé plusieurs années à l’école. Pour combler ces lacunes, le programme « Enseignement au Bon Niveau » (TaRL) de son équipe collabore avec les écoles et les collectivités locales pour fournir des compétences de base en lecture et en arithmétique, en veillant à ce qu’aucun enfant ne soit laissé pour compte. Ce modèle systématique et reproductible touche des millions d’enfants chaque année et s’est répandu dans le monde entier.

Avec le soutien du Prix Yidan, le Dr Banerji prévoit de renforcer et d’étendre le travail de Pratham auprès des jeunes enfants afin que des bases solides puissent être construites tôt dans la vie d’un enfant. Elle pense que cela contribuera de manière significative à l’objectif de voir « chaque enfant à l’école et en train de bien apprendre ».

Chaque lauréat recevra 30 millions de dollars Hongkongais (environ 3,9 millions de dollars américains), dont la moitié est un fonds de projet – permettant à une série de projets éducatifs innovants et progressistes de se développer et de soutenir des millions d’apprenants dans le monde. Ensemble, les projets des lauréats contribuent à rendre le monde meilleur grâce à l’éducation.

The independent Yidan Prize Judging Committee comprises internationally recognized education experts.

Tous les lauréats se joindront aux membres du Yidan Council of Luminaries pour travailler en collaboration et parler d’une voix collective – pour faire la lumière sur l’importance de restaurer et de repenser l’éducation avec des idées novatrices.

La période de nomination pour le Prix Yidan 2022 débute le 19 octobre

Les candidatures pour le prix Yidan 2022 seront ouvertes du 19 octobre 2021 à mars 2022.

À propos de la Fondation du Prix Yidan et du Prix Yidan

La Yidan Prize Foundation est une fondation éducative philanthropique mondiale. Grâce à son prix et à son réseau d’innovateurs, il soutient les idées et les pratiques dans le domaine de l’éducation, en particulier celles qui ont le pouvoir de changer positivement les vies et la société.

Le Prix Yidan est un hommage à l’éducation inclusive qui reconnaît les personnes ou les équipes qui ont contribué de façon importante à la théorie et à la pratique de l’éducation.

https://yidanprize.org

Logo – https://mma.prnewswire.com/media/1636915/Yidan_Prize_Logo.jpg
Photo – https://mma.prnewswire.com/media/1636917/2021_Yidan_Laureates.jpg
Photo – https://mma.prnewswire.com/media/1636916/Yidan_Judging_Committee.jpg